Myriad Expands CDx Collaboration with AstraZeneca, Builds New Lab | GenomeWeb

NEW YORK (GenomeWeb News) – Myriad Genetics announced that it will build a new laboratory at its Salt Lake City facility within which the company will develop companion diagnostics in line with US Food and Drug Administration's regulations.

The new lab build out, according to Myriad, expands its non-exclusive collaboration with AstraZeneca to study the drug olaparib in Phase III trials using Myriad's BRACAnalysis test to pick out best responders to the treatment. The partners did not disclose the specific terms of the expanded collaboration.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.